A major breakthrough for the biotechnology and agri-food sectors, born from a scientific collaboration in Canada.
Quebec, April 3, 2025 – Bioeureka today unveils a major innovation that promises to transform the food quality control sector: the first intelligent platform dedicated to the rapid and reliable identification of pathogens in laboratory settings. This breakthrough is the result of an exceptional collaboration between several centres of excellence in biotechnology and artificial intelligence: Mila, GénieLab and BioLab in Ottawa, as well as Chrono Innovation in Montreal.
Designed to meet the practical needs of food testing laboratories, this technology reduces compliance certificate issuance times by 50% and processing costs by 40%, while maintaining high standards of accuracy. It represents a significant step toward making advanced laboratory tools more accessible, particularly for small and medium-sized businesses.
“We created Bioeureka with a strong conviction: innovation should not be reserved for industry giants. Thanks to AI, we are putting a powerful tool into the hands of SMEs to help them gain efficiency, precision, and speed. This is a revolution for the food quality control sector.”
— Mohamed M. Diallo, Founder and CEO of Bioeureka
A Technology Poised to Transform the Global Industry
Developed by a multidisciplinary team of experts, the Bioeureka platform automates the most labor-intensive steps of microbiological analysis, allowing technicians to focus on validating results rather than performing repetitive handling tasks. Initial tests conducted with BioLab in Ottawa demonstrated remarkable efficiency in both speed and reliability.
While more than 90% of laboratories still rely on manual methods that are often costly and time-consuming, Bioeureka positions itself as a driver of digital transformation. The accessibility of its platform enables small and medium-sized businesses to compete with major market players by leveraging artificial intelligence tools that were previously out of reach.
AI can predict the likelihood of disease outbreaks by analyzing patterns and trends in data. For example, machine learning models can be trained on historical health data to identify patterns that precede disease epidemics. This predictive capability enables healthcare providers to take proactive measures to prevent or mitigate the impact of diseases.
AI can analyze a patient’s genetic information and medical history to predict their risk of developing certain diseases. This information can be used to create personalized treatment plans tailored to the individual’s unique genetic profile and health condition. Personalized medicine not only improves treatment effectiveness, but also reduces the risk of adverse drug reactions.
To support this launch, Bioeureka is offering a special promotion: 500 free analyses during the first month for companies wishing to discover the platform and test its effectiveness in a real-world setting.
“From our very first conversations, I recognized Bioeureka’s major potential to transform the microbiology industry. This is a world-class solution, developed by an exceptional team. Supporting this vision of impact and innovation felt natural to me.”
— Olivier Benloulou, Board Member and Experienced Technology Investor
Bioeureka at SIAL Toronto
The Bioeureka team will present its platform at SIAL Canada in Toronto at the end of April. On-site demonstrations will be held, along with scheduled meetings with media representatives, investors, and industry partners.
